Bioprocess Control Specialist Focuses on Single-Use Sensors
Lab Automation through Single-Use Sensors and Monitors
Lonza Upgrades Live-Cell Imaging System
For Obtaining Better Cell-Culture Analyses
Antibody Characterization Balances Rigor and Reason
Emphasizes a Combination of Antibody-Dependent and -Independent Testing Methods
Cancer Immunotherapy Spurs Work on Better Animal Models
GEN Spoke to Several Researchers on Advances in Engineered Animal Models Used to Study Novel Cancer Im-munotherapies
Nanobiotech in the U.S.
FDA’s recently enacted budget for this fiscal year included some good news for proponents of nanotechnology as well as the promise for more in the years ahead. The agency’s National Center for Toxicological Research (NCTR), which conducts research on new medical products like nanomaterials, was approved $60 million for fiscal 2012, flat compared to FY ’11. Sen. Mark Pryor (D-AR) also inserted language in the House-Senate conference report endorsing the development of a nanotechnology core facility. One such site became operational last fiscal year, the other is set for FY 2012. These are among efforts to maintain U.S. leadership in nanotech. Europe is the nearest-term threat, but China, Singapore, and Taiwan are among others. What are your predictions?